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Summary
Introduction TAS-114 is a potent inhibitor of deoxyuridine triphosphatase, which is a gatekeeper protein preventing uracil and 5-
fluorouracil (5-FU) misincorporation into DNA. TAS-114 has been suggested to enhance the antitumor activity of 5-FU. This
randomized, phase 2 study investigated TAS-114 plus S-1 (TAS-114/S-1) vs. S-1 in non-small-cell lung cancer (NSCLC) patients.
MethodsPatientswith advancedNSCLC, previously treatedwith ≥ 2 regimens, were randomized 1:1 to receive TAS-114 (400mg)/S-1
(30 mg/m2) or S-1 (30 mg/m2). Progression-free survival (PFS, independent central review) was the primary endpoint. Secondary
endpoints included disease control rate (DCR), overall survival (OS), overall response rate (ORR), and safety. Results In total, 127
patients received treatment.Median PFSwas 3.65 and 4.17months in the TAS-114/S-1 and S-1 groups, respectively (hazard ratio [HR]
1.16, 95% confidence interval [CI] 0.71–1.88; P = 0.2744). DCR was similar between groups (TAS-114/S-1 80.3%, S-1 75.9%) and
median OS was 7.92 and 9.82 months for the TAS-114/S-1 and S-1 groups, respectively (HR 1.31, 95% CI 0.80–2.14; P = 0.1431).
The ORR was higher in the TAS-114/S-1 group than the S-1 group (19.7% vs. 10.3%), and more patients with tumor shrinkage were
observed in the TAS-114/S-1 group. Incidence rates of anemia, skin toxicities, and Grade ≥ 3 treatment-related adverse events were
higher in the TAS-114/S-1 group compared with the monotherapy group. Conclusions Although the TAS-114/S-1 combination
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improved the response rate, this did not translate into improvements in PFS. Clinical Trial Registration No. NCT02855125
(ClinicalTrials.gov) registered on 4 August 2016.
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Introduction
Non-small-cell lung cancer (NSCLC) is the leading cause of
cancer incidence and cancer-related mortality worldwide [1].
Recently, the development of immunotherapy and its combi-
nation with cytotoxic chemotherapies has garnered new op-
tions for therapeutics in advanced NSCLC [2]. However, de-
spite recent advances, most patients still progress after treat-
ment, and cytotoxic chemotherapies remain essential in
NSCLC treatment algorithms [3, 4]. Thus, highly efficacious,
well-tolerated chemotherapies are still warranted.
S-1 is an oral 5-fluorouracil (5-FU) derivative that is widely
used for the treatment of various solid tumors, including
NSCLC [5]. Recently, a phase 3 study of S-1 monotherapy
demonstrated non-inferiority compared with docetaxel in pa-
tients with NSCLC; thus, S-1 is considered a standard chemo-
therapy option in East Asia [6].
TAS-114 is a potent inhibitor of deoxyuridine
triphosphatase (dUTPase), which is a gatekeeper protein that
prevents uracil and 5-FU misincorporation into DNA. TAS-
114 inhibits the conversion of deoxyuridine triphosphate
(dUTP) and 5- f luoro-dUTP (FdUTP) in to the i r
monophosphate forms. TAS-114 itself does not have antitu-
mor activity; however, when it is combined with 5-FU deriv-
atives, it can increase the amount of FdUTP in the tumor for
selective incorporation into DNA, thus enhancing the antitu-
mor effect [7, 8].
Two previous phase 1 studies of TAS-114 combined with
S-1, conducted separately in Europe and Japan, concluded that
the recommended dose was TAS-114 240 mg/m2 plus S-1 30
mg/m2. The combination of TAS-114 and S-1 demonstrated
promising antitumor activity, with a manageable safety profile
in heavily pretreated solid tumors. The overall response rate
(ORR), including unconfirmed partial response (PR), in
NSCLC was approximately 30% [9, 10]. Based on these re-
sults, we conducted a randomized phase 2 study to investigate
the combination of TAS-114 with S-1 vs. S-1 monotherapy in
patients with advanced NSCLC.
Materials and methods
Study design
This was an open-label, multicenter, international, random-
ized phase 2 study conducted at 28 sites across five countries
(Japan, France, Spain, Italy, and the United States). Eligible
patients were enrolled by the investigators and randomly
assigned to TAS-114 plus S-1 (TAS-114/S-1) or S-1 alone in
a 1:1 ratio. The random allocation sequence was generated,
and treatment assignment performed centrally using a dynam-
ic allocation method (biased coin) via an interactive voice/web
response system. Patients were stratified by histological sub-
type (squamous vs. non-squamous) and region (Europe/
United States vs. Japan).
The study was approved by independent ethics committees
or institutional review boards at each site. The study conduct
was in accordance with Good Clinical Practice Guidelines and
the Declaration of Helsinki. All patients provided written in-
formed consent before enrollment (ClinicalTrials.gov identifi-
er NCT02855125).
Patients
Key eligibility criteria were age ≥ 18 years (≥ 20 years in
Japan), histologically confirmed advanced or metastatic
NSCLC; prior treatment with at least two systemic therapies
(one of which must be platinum doublet and either
pemetrexed, docetaxel, or immunotherapy) for advanced or
metastatic NSCLC; Eastern Cooperative Oncology Group
performance status (ECOG PS) of 0–1; adequate bonemarrow
function (absolute neutrophil count ≥ 1500/mm3, hemoglo-
bin ≥ 10.0 g/dL, platelets ≥ 100,000/mm3); adequate liver
function (total bilirubin ≤ 1.5 × upper limit of normal [ULN],
aspartate aminotransferase/alanine aminotransferase ≤ 3 ×
ULN [in patients with existent liver metastases, ≤ 5 ×
ULN]); and adequate renal function (calculated creatinine
clearance ≥ 50 mL/min [Cockcroft-Gault]). All eligibility
criteria are listed in Online Resource Text S1.
Treatment
TAS-114 400 mg and/or S-1 30 mg/m2 were concurrently
administered orally twice daily under fasting conditions in a
schedule consisting of 14 consecutive days of treatment
followed by a 7-day rest. TAS-114 dosing was switched from
body surface area (BSA)-based to a flat-fixed dose to avoid
the risk of dosing errors. TAS-114 400 mg was equivalent to
240 mg/m2, which is the recommended dose of TAS-114 for
an overall mean BSA of 1.69 m2 based on the results of the
two phase 1 studies [9, 10]. In these studies, there was no
correlation between the oral clearance of TAS-114 and BSA.
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Treatment was repeated every 3 weeks until disease progres-
sion, intolerable toxicities, or withdrawal of consent. No
crossover was permitted.
Endpoints and study assessments
The primary endpoint was progression-free survival (PFS) as
determined by independent central review (ICR). Secondary
endpoints were ORR, disease control rate (DCR), overall sur-
vival (OS), and safety. PFS was defined as the time from
randomization to the date of first radiologic disease progres-
sion or death, whichever occurred first. ORR was defined as
the proportion of patients with complete response (CR) or PR.
DCR was defined as the proportion of patients with CR, PR,
or stable disease. OS was defined as the time from randomi-
zation to death. Tumor shrinkage for each patient and its cor-
relation with PFS by ICR was assessed as an exploratory
analysis.
Tumor assessments were performed every 6 weeks from
the first study drug administration until disease progression
according to the RECIST version 1.1. Assessment results
were evaluated by independent central radiologists
(Medpace Imaging Core Lab, Ohio, USA) and by the inves-
tigators at each site.
Adverse events (AEs) were reported using the verbatim
term, and the severity was graded based on the National
Cancer Institute Common Terminology Criteria for Adverse
Events version 4.03. AEs were coded by preferred term ac-
cording to the Medical Dictionary for Regulatory Activities
(MedDRA®: trademark is registered by the International
Federation of Pharmaceutical Manufacturers & Associations
on behalf of the International Council for Harmonisation) ver-
sion 19.0.
Statistical analysis
The sample size was estimated based on PFS. A total sample
size of 124 patients was required to provide 60 events (pro-
gressive disease or death) by ICR for the primary analysis,
which corresponds to 71 events based on investigator review
under the assumption that the discrepancy in progressive dis-
ease events between ICR and investigator review is 15%.
Based on the results of previous clinical trials [9–13], the
median PFS in the S-1 group was estimated to be 2.2 months,
and 4.2 months in the TAS-114/S-1 group, corresponding to a
hazard ratio (HR) of 0.524, with 80% statistical power and a
one-sided significance level of 0.05.
The PFS and OS analyses were conducted on an intent-to-
treat (ITT) population, of all patients randomized in the study,
regardless of whether they received any study treatment or
not. The ORR was analyzed based on the tumor response-
evaluable population, defined as all patients in the ITT popu-
lation with measurable disease (at least one target lesion) at
baseline and with at least one tumor evaluation. We performed
a sensitivity analysis in which PFS, ORR, and DCR were also
analyzed based on the investigator’s assessment. The safety
analysis was conducted on an as-treated population, defined as
all patients who received at least one dose of the study drug.
PFS and OS were estimated using the Kaplan–Meier meth-
od; HRs were estimated using a Cox proportional hazards
model stratified by geographical region and histological sub-
types. Medians (with 95% confidence intervals [CIs]) were
calculated using the Brookmeyer-Crowley method. For
between-group comparisons, the stratified log-rank test with
a one-sided significance level of 5%was used for PFS and OS,
and Fisher’s exact test for ORR and DCR. All statistical anal-
yses were performed using SAS software version 9.4 in the
UNIX environment (SAS Institute Inc., North Carolina,
USA).
Results
Patients
From August 2016 to July 2017, a total of 128 patients were
randomly assigned to treatment: 64 patients each were
assigned to the TAS-114/S-1 and S-1 groups (Fig. 1). A total
of 127 patients received at least one study treatment; one pa-
tient in the S-1 group was found ineligible, and thus,
discontinued before the initial study drug administration.
Twenty patients were receiving treatment by the cut-off date
for primary analysis (30 September 2017). Baseline character-
istics were generally balanced in the two groups, except for
sex, ECOG PS, and epidermal growth factor receptor (EGFR)
mutation status (Table 1). More than half of the patients had
received a prior systemic regimen as fourth-line or further
therapy. Over 70% of patients had received prior programmed
death 1/programmed death-ligand 1 antibodies.
Treatment
In the TAS-114/S-1 and S-1 groups, patients received me-
dians of 4.0 (range, 1–14) and 3.0 (range, 1–12) treatment
cycles, respectively. In the TAS-114/S-1 group, the me-
dians for relative dose intensity (RDI) of TAS-114 and
S-1 were 85.9% and 84.8%, respectively. In the S-1
group, the median RDI was 95.5%. By the data cut-off
date, 107 patients had discontinued study treatment. In
both groups, the main reason for discontinuation was dis-
ease progression. After study discontinuation, 54.5% and
65.4% of patients in the TAS-114/S-1 and S-1 groups,
respectively, received other anticancer treatments. The
median duration for survival follow-up was 9.03 months.
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Efficacy
At the data cut-off date, 73 PFS events were observed by ICR.
The median PFS was 3.65 months in the TAS-114/S-1 group
and 4.17 months in the S-1 group (HR 1.16, 95% CI 0.71–
1.88; P = 0.2744) (Fig. 2a). In the subgroup analyses, the data
were generally similar to that of the overall population (Fig.
2b). The DCR was similar between TAS-114/S-1 and S-1
groups (80.3% vs. 75.9%), whereas patients in the TAS-114/
S-1 group showed higher ORR than those in the S-1 group
(19.7% vs. 10.3%) (Table 2). Additionally, Fig. 3a and b
shows the relationship between tumor shrinkage and PFS by
RECIST for each patient. Investigator-assessed results were
3.48months vs. 2.66 months for PFS (HR 0.79, 95% CI 0.52–
1.21; P = 0.1352), 78.7% vs. 59.3% for DCR, and 19.7% vs.
10.2% for ORR (Table 2; Online Resource Figures S1 and
S2).
The data cut-off for OS was 30 November 2017, at which
time 65 events were observed. The median OSwas 7.92 in the
TAS-114/S-1 group and 9.82 months in the S-1 group (HR
1.31, 95% CI 0.80–2.14; P = 0.1431) (Online Resource
Figures S3 and S4).
Safety
Treatment-related AEs (TRAEs) occurring in ≥ 10% of pa-
tients are shown in Table 3. The incidence rates of anemia,
skin toxicities, and Grade ≥ 3 TRAEs were higher in the TAS-
114/S-1 group compared with the monotherapy group.
Serious TRAEs were reported in 17.2% of patients in the
TAS-114/S-1 group, and in 6.7% in the S-1 group. In the
TAS-114/S-1 group, two patients each reported treatment-
related serious anemia (3.1%), diarrhea (3.1%), and maculo-
papular rash (3.1%) of any grade. More patients in the TAS-
114/S-1 group had dose reductions/interruptions (mainly due
to skin toxicities) than patients in the S-1 group (reductions:
31.3% vs. 11.1%; interruptions: 45.3% vs. 14.3%) (Online
Resource Table S1). No treatment-related death was reported.
Discussion
The present randomized study is the first to evaluate the effect
of a dUTPase inhibitor in combination with a 5-FU derivative.
Favorable tumor response and shrinkage trends were observed
in the TAS-114/S-1 group; however, they did not translate into
an improved PFS. No difference in duration of response was
observed, and the early progressive disease (< 3 months) rate
was similar across groups. A possible reason is that more
patients in the TAS-114/S-1 group experienced dose
reductions/interruptions due to AEs, and these results may
have affected the primary endpoint result.
According to the investigator review, the median PFS was
3.48 months for the TAS-114/S-1 group and 2.66 months for
the S-1 group (95 PFS events). In the S-1 group, a significant
difference in the median PFS (1.51-month difference) was
observed between the ICR and investigator review, in contrast
with the TAS-114/S-1 group (0.17-month difference). This
may be a result of treatment bias owing to lack of blinding.
In fact, the number of censored cases was higher in the S-1
group by ICR; therefore, the PFS in the S-1 group was pre-
sumably influenced by informative censoring [14].
Fig. 1 CONSORT flow diagram
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The OS result was immature at the data cut-off, but
was lower in the TAS-114/S-1 group (not statistically sig-
nificant). This difference between groups might have
resulted from the percentage and timing of patients receiv-
ing anticancer treatment after discontinuation, and some
imbalances in patient background characteristics that are
Table 1 Baseline demographic
characteristics (intent-to-treat
population)
Characteristic TAS-114/S-1
(n = 64)
S-1
(n = 64)
Age (years), median 65.5 64.0
Age group, n (%)
< 65 years 28 (43.8) 33 (51.6)
≥ 65 years 36 (56.3) 31 (48.4)
Sex, n (%)
Male 41 (64.1) 48 (75.0)
Female 23 (35.9) 16 (25.0)
Region, n (%)
Western 34 (53.1) 34 (53.1)
Asian 30 (46.9) 30 (46.9)
ECOG PS, n (%)
0 12 (18.8) 17 (26.6)
1 52 (81.3) 47 (73.4)
Histology subtype, n (%)
Squamous cell carcinoma 14 (21.9) 14 (21.9)
Adenocarcinoma 48 (75.0) 48 (75.0)
Large cell carcinoma 0 1 (1.6)
Carcinoid tumor 1 (1.6) 0
Other 1 (1.6) 1 (1.6)
EGFR mutation status, n (%)
Positive 7 (10.9) 12 (18.8)
Negative 46 (71.9) 38 (59.4)
Unknown 11 (17.2) 14 (21.9)
ALK translocation status, n (%)
Positive 2 (3.1) 0
Negative 44 (68.8) 43 (67.2)
Unknown 18 (28.1) 21 (32.8)
Brain metastases, n (%) 6 (9.4) 7 (11.0)
Number of prior systemic regimens, n (%)
1 0 0
2 24 (37.5) 19 (29.7)
3 19 (29.7) 17 (26.6)
4 14 (21.9) 15 (23.4)
≥ 5 7 (10.9) 13 (20.3)
Main prior systemic anti-cancer agent, n (%)
Platinum 64 (100) 64 (100)
PD-1/PD-L1 antibodies 46 (71.9) 49 (76.6)
Pemetrexed 48 (75.0) 47 (73.4)
Docetaxel 33 (51.6) 38 (59.4)
EGFR-TKI 7 (11.0) 11 (17.2)
ALK-TKI 2 (3.1) 0
ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR,
epidermal growth factor receptor; PD-1, programmed death 1; PD-L1, programmed death ligand 1; TKI, tyrosine
kinase inhibitor
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known to be prognostic factors, such as EGFR mutation
[15, 16]. Based on the efficacy and safety results, the
sponsor decided to terminate the TAS-114/S-1
combination, and all five patients remaining in TAS-114
treatment were switched to S-1 alone after the primary
analysis.
Fig. 2 (a) Progression-free survival by ICR (intent-to-treat population),
(b) forest plot of hazard ratios for treatment effect on progression-free
survival (ICR). ALK, anaplastic lymphoma kinase; CI, confidence
interval; ECOG, Eastern Cooperative Oncology Group; EGFR,
epidermal growth factor receptor; HR, hazard ratio; ICR, independent
central review; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase
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Although the patient numbers were very limited (7 vs. 12
patients), the subgroup analysis showed that EGFR-mutant
patients tended to achieve longer PFS (11.6 months vs. 2.6
months; HR 0.18; 95% CI 0.02–1.63) and OS (not reached vs.
10.6 months; HR 0.12; 95% CI 0.01–0.99) in the TAS-114/S-
1 group vs. the S-1 group. It has been reported that advanced
NSCLC EGFR-mutant patients present defective DNA-repair
functions [17, 18]. In a preclinical model, suppression of DNA
repair proteins increased its sensitivity to TAS-114 combined
with the 5-FU metabolite 5-fluoro-2’-deoxyuridine [19].
Thus, it is possible that the present favorable effect in patients
withEGFRmutations in the TAS-114/S-1 group resulted from
increased uracil and 5-FU incorporation into DNA.
The overall safety profile in the TAS-114/S-1 group was
consistent with previous phase 1 studies; anemia and skin
toxicities were more commonly observed in this group [9,
10]. These toxicities were considered manageable by dose
modification and standard symptomatic treatment and were
presumed to result from the combination of TAS-114 and
S-1. In exploratory analysis, patients with anemia and/or skin
toxicities in the TAS-114/S-1 group showed a tendency to-
ward longer PFS compared with patients without these toxic-
ities (Online Resource Text S2). Moreover, anemia was also
commonly reported with DNA-damaging agents; it is possible
that the frequent anemia reported with TAS-114/S-1 was at-
tributed to increased DNA damage [20, 21].
Fig. 3 Individual tumor shrinkage and progression-free survival (independent central review) in the (a) TAS-114/S-1 group and (b) S-1 group
Table 2 Overall response rate
and disease control rate by ICR
and INV (tumor response
evaluable population)
ICR INV
TAS-114/S-1
(n = 61)
S-1
(n = 58)
TAS-114/S-1
(n = 61)
S-1
(n = 59)
Overall response rate,
% (95% CI)
19.7
(10.6–31.8)
10.3
(4.0–21.5)
19.7
(10.6–31.8)
10.2
(3.9–21.2)
CR 1 (1.6) 0 0 0
PR 11 (18.0) 6 (10.3) 12 (19.7) 6 (10.2)
SD 37 (60.7) 38 (65.5) 36 (59.0) 29 (49.2)
PD 12 (19.7) 13 (22.4) 13 (21.3) 23 (39.0)
Disease control rate
(CR + PR + SD), % (95% CI)
80.3
(68.2–89.4)
75.9
(64.2–87.3)
78.7
(66.3–88.1)
59.3
(46.6–73.0)
CI, confidence interval; CR, complete response; ICR, independent central review; INV, Investigator review; PR,
partial response; PD, progressive disease; SD, stable disease
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The present study had several limitations. These include
the relatively small sample size that may have prevented the
identification of some group differences, the open-label de-
sign that may have introduced bias from the investigators,
and the background characteristic imbalances that may have
affected the primary endpoint results.
Conclusions
Although the TAS-114/S-1 combination did result in a higher
response rate and tumor shrinkage in this advanced NSCLC
population, it did not improve PFS or OS.
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